Your browser doesn't support javascript.
loading
A review of immune-related adverse events associated with immunotherapy / 中华肿瘤杂志
Chinese Journal of Oncology ; (12): 17-21, 2020.
Article in Chinese | WPRIM | ID: wpr-799029
ABSTRACT
Immune checkpoint inhibitors have been approved for clinical application in China. However, the increased immune-related adverse event (irAE) needs more attention. This review summarized the incidence, characteristic clinical manifestation and treatment of irAEs associated with programmed cell death protein-1(PD-1) and programmed cell death ligand-1(PD-L1) inhibitors. To have a deep insight into irAE, the potential mechanisms, the different incidences of cancer types, influencing factors and the direction of future research were also discussed here to provide guidance for clinical oncologist to identify and monitor irAE.

Full text: Available Index: WPRIM (Western Pacific) Type of study: Practice guideline / Prognostic study Language: Chinese Journal: Chinese Journal of Oncology Year: 2020 Type: Article

Similar

MEDLINE

...
LILACS

LIS

Full text: Available Index: WPRIM (Western Pacific) Type of study: Practice guideline / Prognostic study Language: Chinese Journal: Chinese Journal of Oncology Year: 2020 Type: Article